Announcements Trials
Browse Landscape

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

OTHER 29INDUSTRY 3NIH 1

Study Type

Observational 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Tomography, Optical Coherence × Clear all
NCT01506700 2019-07-26

Real Time Optical Coherence Tomography (OCT) of Human Tissue

Diagnostic Photonics, Inc.

Terminated
5 enrolled
Breast

Breast Neoplasms

NCT02313116 2019-07-18

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

Diagnostic Photonics, Inc.

Suspended
50 enrolled
Breast

Breast Neoplasms

NCT01699867 2015-01-06

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

Diagnostic Photonics, Inc.

Completed
50 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡